EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share (EDAP)
Last edap tms s.a. - american depositary shares, each representing one ordinary share earnings: 3/30 04:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.edap-tms.com/investor-relations
Company Research
Source: GlobeNewswire
60 Patients Completed Enrollment in Under 9 Months Study Results Expected in the Second Half of 2024 LYON, France, February 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis. The ongoing Phase 3 study (NCT05755958) is a comparative, randomized, double blind trial, with the primary objective of evaluating acute pelvic pain levels in 60 patients. Select treated patients are followed three months post-HIFU treatment in comparison to a sham group. The last patient was treated in January. Study results are expected in the second half of 2024. “We are pleased to announce the completion of enrollment in our Phase 3 study, which represents a significant clinical milestone for our company,” said Ryan Rhodes, Chief Executive Officer of EDAP
Show less
Read more
Impact Snapshot
Event Time:
EDAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDAP alerts
High impacting EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share news events
Weekly update
A roundup of the hottest topics
EDAP
News
- Edap Tms S.A. (NASDAQ: EDAP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024GlobeNewswire
- EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual MeetingGlobeNewswire
- Edap Tms S.A. (NASDAQ: EDAP) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
EDAP
Earnings
- 3/27/24 - Miss
EDAP
Sec Filings
- 4/17/24 - Form EFFECT
- 4/5/24 - Form F-3
- 3/28/24 - Form 20-F
- EDAP's page on the SEC website